(S022) Gender Differences in Time to Promotion and Scholarly Activity Among Academic Radiation Oncologists

Publication
Article
OncologyOncology Vol 30 No 4_Suppl_1
Volume 30
Issue 4_Suppl_1

Although the female RO full professors in our cohort were similar overall in terms of productivity and NIH funding to their male colleagues, they tended to have longer times to promotion earlier in their careers at lower academic ranks. Women may experience barriers to productivity early in their careers that may delay promotion.

Subha Perni, Reshma Jagsi, MD, DPhil, Mehee Choi, MD, Lynn D. Wilson, MD, Charles R. Thomas, Jr, MD, Clifton D. Fuller, MD, PhD, Emma B. Holliday, MD; Department of Radiation Oncology, Columbia University/New York Presbyterian Hospital; Department of Radiation Oncology, University of Michigan; Department of Radiation Oncology, Loyola University Chicago; Department of Therapeutic Radiology, Yale School of Medicine and Yale Cancer Center; Department of Radiation Medicine, Knight Cancer Institute, Oregon Health and Science University; Division of Radiation Oncology, UT MD Anderson Cancer Center

PURPOSE: To characterize the longitudinal relationship by gender between publication productivity, NIH funding, and academic promotion of current US academic professors of radiation oncology (RO).

METHODS: For full professors of RO departments, institutional websites were accessed to obtain training information and promotion dates. A commercial database (SCOPUS, Elsevier BV, Amsterdam, the Netherlands) was used to obtain productivity metrics, including publication number, citation number, and Hirsch index (h-index) at the time of each promotion, and National Institutes of Health (NIH) RePORTER (Research Portfolio Online Reporting Tools) was used to obtain NIH funding information. Pearson chi-square test and Wilcoxon rank-sum tests were used for comparisons of variables between men and women.

RESULTS: For 166 RO faculty full professors, there were no significant differences in degree, additional residency and fellowship training, year of RO residency graduation, number of institutions worked at as faculty, NIH funding status, number of publications, citations, h-indices, or m-indices. Women had a longer median time to promotion from assistant to associate professor when compared with men (8 yr, interquartile range [IQR]: 6–11 vs 6 yr, IQR: 5–8 yr; P = .049), as well as longer median time from associate to full professor (6 yr, IQR: 6–11 yr vs 5 yr, IQR: 4–6 yr; P = .004). However, there was no significant difference in time to appointment as chairperson. The h-index and NIH funding at promotion were not significantly different by gender at any of the promotion levels.

CONCLUSIONS: Although the female RO full professors in our cohort were similar overall in terms of productivity and NIH funding to their male colleagues, they tended to have longer times to promotion earlier in their careers at lower academic ranks. Women may experience barriers to productivity early in their careers that may delay promotion. 

Proceedings of the 98th Annual Meeting of the American Radium Society - americanradiumsociety.org

Articles in this issue

(S002) A 15-Year Review of Radiation Therapy for Keloids at Two Institutions
(S003) Single-Fraction Radiation Therapy for the Treatment of Multiple Myeloma Bony Metastases Provides Pain Control and Decreases Time to Chemotherapy
(S001) Prognostic Value of Pretreatment Serum Inflammatory Markers in Patients Receiving Radiation Therapy for Oropharyngeal Cancer
(S004) Trend in Second Malignancy Risk for Head and Neck Cancer With Increased Utilization of IMRT: Analysis of SEER Database
(S005) Comparison of Legal Needs of a Group of Patients With Cancer: Economic and Geographic Factors
(S006) Mission Improvement: Lessons From Initiating a Resident-Led Quality Improvement Project on Smoking Cessation at a County Hospital
(S007) Results of a Phase II Trial Using Cetuximab Plus Docetaxel With Low-Dose Fractionated Radiation for Recurrent Unresectable Locally Advanced Head and Neck Carcinoma
(S008) The Effect of Simulation and Treatment Delays for Patients With Oropharyngeal Cancer Receiving Definitive Radiation Therapy in the Era of Risk Stratification Using Smoking and Human Papilloma Virus Status
(S009) Intensity-Modulated Radiation Therapy With Stereotactic Body Radiation Therapy Boost for Unfavorable Prostate Cancer: A Report on Three-Year Toxicity
(S011) Comparative Study Between Ileal Conduit and Indiana Pouch After Cystectomy for Patients With Carcinoma of Urinary Bladder
(S010) Computed Tomography–Assessed Measures of Bone Mineral Density and Muscle Mass as Predictors of Survival in Men With Prostate Cancer
(S012) Quantitative Imaging to Evaluate the Malignant Potential of Pancreatic Cysts
(S013) Spine Stereotactic Radiosurgery With Concurrent Tyrosine Kinase Inhibitors for Metastatic Renal Cell Carcinoma
(S014) The Impact of Radiation Therapy on Survival in Surgically Resected, High-Risk Patients With Ampullary Adenocarcinoma: A Population-Based Analysis
(S016) The Impact of Stereotactic Body Radiation Therapy on Overall Survival in Patients With Locally Advanced Pancreatic Cancer
Related Videos
Barbara Smith, MD, PhD, spoke about the potential use of pegulicianine-guided breast cancer surgery based on reports from the phase 3 INSITE trial.
Patient-reported symptoms following surgery appear to improve with the use of perioperative telemonitoring, says Kelly M. Mahuron, MD.
Treatment options in the refractory setting must improve for patients with resected colorectal cancer peritoneal metastasis, says Muhammad Talha Waheed, MD.
Although immature, overall survival data from the KEYNOTE-868 trial may support the use of pembrolizumab plus chemotherapy in patients with endometrial cancer.
Dostarlimab plus chemotherapy appears to yield favorable overall survival in patients with mismatch repair proficient endometrial cancer.
Some patients with large B-cell lymphoma may have to travel a great distance for an initial evaluation for CAR T-cell therapy.
Brian Slomovitz, MD, MS, FACOG discusses the use of new antibody drug conjugates for treating patients with various gynecologic cancers.
Education is essential to referring oncologists manage toxicities associated with CAR T-cell therapy for patients with large B-cell lymphoma.
There is no absolute age cutoff where CAR T cells are contraindicated for those with large B-cell lymphoma, says David L. Porter, MD.
David L. Porter, MD, emphasizes referring patients with large B-cell lymphoma early for CAR T-cell therapy consultation.
Related Content